TIMIC
2009
Tailored IMmunosuppression in virus-negative Inflammatory Cardiomyopathy
In 85 patients with biopsy-proven virus-negative inflammatory cardiomyopathy and heart failure refractory to conventional therapy, 6 months of prednisone plus azathioprine improved left ventricular ejection fraction at 6 months compared with placebo.
Result
- Absolute difference
- 24.3 points
- NNT
- 5
Absolute difference and NNT are derived from the event rates.
Also reported: 88 % of treated patients improved versus none on placebo.
- Subtopic
- Myocarditis
- Design
- Double-blind, placebo-controlled RCT with baseline and 6-month endomyocardial biopsy
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2025 Myo/Pericarditis
- Source
- Frustaci A, Russo MA, Chimenti C. Eur Heart J. 2009;30(16):1995-2002.doi 10.1093/eurheartj/ehp249
Discussion & critique
Single-centre, small, with an echocardiographic surrogate endpoint and no hard outcomes, and the strategy only works where endomyocardial biopsy with viral PCR is routine. It is the only randomised trial showing that immunosuppression reverses virus-negative inflammatory cardiomyopathy and is the direct basis for the biopsy-guided pathway.